Evidence map›Paper›PMID 29954866›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Targeting the IL33-NLRP3 axis improves therapy for experimental cerebral malaria.

Patrick Strangward, Michael J Haley, Manuel G Albornoz, Jack Barrington, Tovah Shaw, Rebecca Dookie, Leo Zeef, Syed M Baker, Emma Winter, Te-Chen Tzeng and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 63 citations in OpenAlex.

  1. Targeting IL-33 in Precision Neuroimmunology: Cellular Mechanisms and Therapeutic Strategies for CNS Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. IL-33 Signaling Inhibition Leads to a Preeclampsia-Like Phenotype in Pregnant Rats.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. NLRP3 inhibition improves maternal hypertension, inflammation, and vascular dysfunction in response to placental ischemia.American journal of physiology. Regulatory, integrative and comparative physiology · 2023
    Article
  15. Review
  16. Article
  17. The NLRP3 inflammasome fires up heme-induced inflammation in hemolytic conditions.Translational research : the journal of laboratory and clinical medicine · 2023
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Patrick StrangwardSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Michael J HaleySchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Manuel G AlbornozSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Jack BarringtonSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Tovah ShawSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Rebecca DookieSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Leo ZeefSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Syed M BakerSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Emma WinterSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Te-Chen TzengDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605.
Douglas T GolenbockDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605.
Sheena M CruickshankSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.
Stuart M AllanSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom.ORCID 0000-0001-9646-4456
Alister CraigDepartment of Parasitology, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom.
Foo Y LiewDepartment of Immunology, Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow G12 8TA, United Kingdom.
David BroughSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom; david.brough@manchester.ac.uk kevin.couper@manchester.ac.uk.ORCID 0000-0002-2250-2381
Kevin N CouperSchool of Biological Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, United Kingdom; david.brough@manchester.ac.uk kevin.couper@manchester.ac.uk.
Manchester Academic Health Science Centre · GBUniversity of Massachusetts Chan Medical School · USLiverpool School of Tropical Medicine · GBSoochow University · CN

Funding

Innate Immune Activation in MalariaR01AI079293 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A., GOLENBOCK, DOUGLAS T · 2009 to 2024
$10.9M
Medical Research Council G0900487Medical Research Council MC_PC_16033Medical Research Council MR/L008564/1Medical Research Council MR/L011840/1Medical Research Council MR/N003586/1Medical Research Council MR/R010099/1NIAID NIH HHS R01 AI079293
6 · The paper itself

Abstract

Cerebral malaria (CM) is a serious neurological complication caused by

Indexed as

AnimalsAntimalarialsBrainDisease Models, AnimalDrug Delivery SystemsFemaleGene Expression ProfilingHemeproteinsInterleukin-1betaInterleukin-33MacrophagesMalaria, CerebralMalaria, FalciparumMaleMiceNLR Family, Pyrin Domain-Containing 3 ProteinAntimalarialsHemeproteinshemozoinIL1B protein, mouseIl33 protein, mouseInterleukin-1betaInterleukin-33NLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseIL33inflammasomeinflammationmalariaNLRP3

Identifiers

PMID29954866
PMCPMC6048513
OpenAlexW2807773657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.